All Oncology News

Richard Kim, MD, discusses the standard treatment approaches and unmet needs for patients with resectable colorectal cancer.

Razane El Hajj Chehade, MD, discusses a retrospective study of risk factors for irAEs in patients with metastatic renal cell carcinoma.

A phase 1b trial is evaluating the TIL therapy TBio-4101 plus pembrolizumab in PD-(L)1 inhibitor–resistant head and neck squamous cell carcinoma.

C. Ola Landgren, MD, PhD, discusses the use of quadruplet regimens in patients with newly diagnosed multiple myeloma.

The FDA completed an end-of-phase 2 meeting for botensilimab plus balstilimab in relapsed/refractory microsatellite stable colorectal cancer.

The National Medical Products Administration accepted for review the supplemental new drug application for toripalimab plus bevacizumab in advanced HCC.

The addition of nivolumab to tivozanib did not improve PFS in advanced metastatic renal cell carcinoma following prior immune checkpoint inhibition

A UCSF-led study alerts transwomen and physicians to interpret standard screening guidelines with caution.

Tanios S. Bekaii-Saab, MD, highlights data from the phase 1/2 ARC-9 study which showed promising overall survival data in patients with colorectal cancer.

Ibrutinib plus venetoclax produced durable complete responses in TP53-mutated mantle cell lymphoma.

Odronextamab elicited deep, durable responses in heavily pretreated patients with relapsed/refractory follicular lymphoma.

Brentuximab vedotin plus lenalidomide/rituximab (R2) provided a superior overall survival benefit vs R2 alone in relapsed/refractory DLBCL.

Moritz Fürstenau, MD, discusses 4-year follow-up findings from the phase 3 GAIA/CLL13 trial in patients with CLL.

The BLA for tabelecleucel has been granted priority review for the treatment of patients with Epstein-Barr virus–positive post-transplant lymphoproliferative disease.

Guillermo Garcia-Manero, MD, spotlights 3 key analyses of luspatercept in low-risk myelodysplastic syndrome presented at the 2024 EHA Congress.

Darolutamide plus ADT improved radiologic PFS vs placebo plus ADT in men with metastatic hormone-sensitive prostate cancer enrolled in the phase 3 ARANOTE trial.

U.S. News & World Report named Hackensack Meridian Hackensack University Medical Center the #1 hospital in New Jersey on its annual Best Hospitals list.

The National Comprehensive Cancer Network has published their updated Clinical Practice Guidelines in Oncology for kidney cancer.

Francisco Hernandez-Ilizaliturri, MD, discusses selection and sequencing considerations for bispecific antibodies and CAR T-cell therapies in DLBCL.

Justin M. Watts, MD, discusses phase 1 efficacy and safety data for the oral BET inhibitor INCB057643 in advanced myelofibrosis.

TQB2930 was well tolerated and generated responses in HER2-positive advanced breast cancer.

This roundup includes exclusive insights from nearly 20 clinicians and key data on the top abstracts coming out of the 2024 ASCO Annual Meeting.

Jessica Bauman, MD, found that a new integrated palliative care rotation for hematology/oncology fellows improved their palliative care knowledge.

Bexarotene has been granted marketing authorization in Hong Kong for the treatment of pretreated cutaneous manifestations of cutaneous T-cell lymphoma.

The FDA has awarded fast track designation to the next-generation precision radiopharmaceutical therapy ABD-147 for the treatment of patients with ES-SCLC.

Adjuvant nivolumab plus ipilimumab significantly improved 3-year DMFS rates compared with historical controls in patients with high-risk uveal melanoma.

RMC-6236 led to early antitumor activity with an acceptable safety profile in patients with previously treated pancreatic ductal adenocarcinoma.

The FDA has placed a partial clinical hold on a trial evaluating seclidemstat plus azacitidine in myelodysplastic syndromes or chronic myelomonocytic leukemia.

The addition of ipilimumab to cabozantinib plus nivolumab was safe and showed notable efficacy in patients with rare genitourinary cancers.

Aaron Gerds, MD discusses updated efficacy findings from the prospective randomized phase 3 MANIFEST-2 trial.